Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020221928 - ANTI-LAG-3 BINDING MOLECULES

Publication Number WO/2020/221928
Publication Date 05.11.2020
International Application No. PCT/EP2020/062211
International Filing Date 01.05.2020
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61P 37/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
CPC
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/75
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
75Agonist effect on antigen
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • IMMUTEP S.A.S. [FR]/[FR]
Inventors
  • TRIEBEL, Frédéric
  • BRIGNONE, Chrystelle
Agents
  • THORTON, Neil
Priority Data
1906118.301.05.2019GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-LAG-3 BINDING MOLECULES
(FR) MOLÉCULES DE LIAISON ANTI-LAG-3
Abstract
(EN)
The present disclosure relates to agonistic anti-LAG-3 (CD223) antibodies which inhibit T cell receptor (TCR)-mediated signal transduction in LAG-3 positive T cells through agonism of LAG-3. The antibodies bind specifically to a discontinuous epitope within the extracellular lg superfamily domain D1 of LAG-3 protein, wherein the epitope lies outside a 30 amino acid extra-loop sequence of domain D1 of the LAG-3 protein. Use of the antibodies as medicaments is described.
(FR)
La présente invention concerne des anticorps agonistes anti-LAG-3 (CD223). Les molécules de liaison inhibent la transduction de signaux médiée par le récepteur des lymphocytes T (TCR) dans des lymphocytes T positifs à LAG-3 par agonisme du LAG-3. Les anticorps se lient spécifiquement à un épitope discontinu dans le domaine D1 de la superfamille des Ig extracellulaires d'un LAG-3, l'épitope se situant à l'extérieur d'une séquence extra-boucle de 30 acides aminés du domaine D1 de la protéine de LAG-3. L'invention concerne également l'utilisation des anticorps en tant que médicaments.
Latest bibliographic data on file with the International Bureau